SG Americas Securities LLC Grows Position in Insulet Co. (NASDAQ:PODD)

SG Americas Securities LLC grew its holdings in shares of Insulet Co. (NASDAQ:PODD) by 295.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,892 shares of the medical instruments supplier’s stock after purchasing an additional 17,857 shares during the quarter. SG Americas Securities LLC’s holdings in Insulet were worth $6,237,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Blue Trust Inc. boosted its holdings in Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 58 shares during the period. Venturi Wealth Management LLC lifted its position in shares of Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 133 shares in the last quarter. TD Private Client Wealth LLC boosted its holdings in shares of Insulet by 32.6% in the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after acquiring an additional 56 shares during the period. Friedenthal Financial purchased a new position in shares of Insulet in the fourth quarter valued at $57,000. Finally, Versant Capital Management Inc raised its stake in shares of Insulet by 106.1% during the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock valued at $80,000 after purchasing an additional 157 shares during the period.

Insulet Stock Up 1.1 %

Shares of PODD opened at $280.35 on Friday. The firm has a market cap of $19.66 billion, a P/E ratio of 48.01, a P/E/G ratio of 3.50 and a beta of 1.22. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $282.86. The stock has a 50 day simple moving average of $267.25 and a two-hundred day simple moving average of $235.25. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 EPS for the quarter, beating the consensus estimate of $0.77 by $0.13. The company had revenue of $543.90 million for the quarter, compared to analyst estimates of $518.50 million. Insulet had a net margin of 21.22% and a return on equity of 27.98%. During the same quarter last year, the firm earned $0.71 EPS. On average, analysts forecast that Insulet Co. will post 3.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on PODD shares. JPMorgan Chase & Co. raised their target price on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research note on Thursday, December 12th. Barclays raised their price objective on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Wells Fargo & Company increased their target price on shares of Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. BTIG Research boosted their price target on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, TD Cowen increased their price objective on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday, January 3rd. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $272.81.

Insider Activity

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. This trade represents a 52.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by corporate insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.